IMS reveals how to avoid common launch miscues

Share this article:
Pharma brand share can level off just a few short months after a launch, according to a new study from IMS Health that examines this lifecycle stage. 

With its “What Drives Launch Excellence?” study released in May, IMS Health examined over 4,200 product launches, in 71 therapy areas, across eight countries, over an eight-year period. The study examined several blockbuster brands including Lilly ICOS’ Cialis, Pfizer’s Celebrex and Merck’s Fosamax.

Because the results of the study showed that pharma companies face increasingly short windows of opportunity when launching new products, the “one-size-fits-all” global launch approach no longer works the way it used to.

Drugmakers must address an increasingly complex decision-making process to be successful, Ray Hill, global head, IMS consulting, told MM&M.

“Launch is the lifeblood of any pharmaceutical company industry but pharma just doesn’t seem to get it right,” Hill said.

SIDEBAR: Launch Basics
Market expansion
     Almost half (46%) of outperforming launches are market expanders
Global consistency
    Only 38% of launches were successful in a majority of total countries
Optimize launch window
    Three out of four launches will not improve on the launch trajectory they are on in the initial six months by the end of a two-year period.

Source: IMS Health

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.